What's Happening?
Artios Pharma has secured $115 million in a series D funding round to advance its oncology pipeline. The funds will primarily support the development of alnodesertib, a drug being tested for second-line
pancreatic cancer and third-line colorectal cancer. Previous data showed promising response rates in patients with advanced solid tumors. Additionally, the funding will facilitate a Phase II trial for ART6043, targeting BRCA-mutant HER2-negative breast cancer. The round was led by SV Health Investors, with participation from RA Capital Management and Janus Henderson Investors.
Why It's Important?
The substantial funding for Artios Pharma underscores the growing investment in cancer research and development. By advancing its pipeline, Artios aims to address unmet needs in oncology, potentially offering new treatment options for patients with specific cancer types. The involvement of prominent investors highlights confidence in Artios' approach and the potential impact of its therapies. Success in these trials could lead to significant advancements in cancer treatment, benefiting patients and healthcare providers while driving innovation in the biopharma sector.
